Advertisements

Neo Spray CAF

Quick links to important sections

Neo Spray CAF

Advertisements
Advertisements

Method of action: Ophthalmologicals

Treatment option: Blepharitis, Keratitis, Trachoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Neo Spray CAF

What is Neo Spray CAF? (Overview)

Neo Spray CAF is a medicated nasal spray formulated as a combination drug product to provide quick, symptomatic relief from nasal congestion. It is typically available over-the-counter (OTC) for short-term use in situations such as a severe head cold or acute sinus flare-up.


Quick Facts

Property Description
Active Ingredients Naphazoline, Camphor, Eucalyptol (Cineole)
Form Nasal Spray
Pharmacological Class Alpha-Adrenergic Agonist (Decongestant) + Topical Counterirritants
Common Use Symptomatic relief of temporary nasal congestion
Composition Feature Combination of therapeutic and aromatic agents

Distinctive Composition and Recognition

The primary active component is Naphazoline. This ingredient belongs to the sympathomimetic amine class and is used specifically to relieve redness and irritation in the nose caused by conditions like the common cold, allergies, and hay fever. This action is clinically recognized for its rapid onset in reducing nasal airflow resistance by causing local vasoconstriction, which shrinks swollen tissue.

Neo Spray CAF is distinguished by its combination of ingredients that offer both therapeutic action and sensory relief. The secondary components, Camphor and Eucalyptol (cineole), are aromatic compounds. Eucalyptol is an organic compound with a unique penetrating aroma that may give a feeling of clearer breathing when applied topically. This combination formula, containing both a decongestant and aromatic agents, targets immediate symptom management.

Advertisements

What side effects are possible with Neo Spray CAF?

Possible Side Effects and Safety Information

The safety profile for Neo Spray CAF, which contains the active decongestant Naphazoline, is defined by effects categorized into local reactions and less common systemic effects. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.


Adverse Reaction Classifications

Category Description (Regulatory Status)
Common Transient local effects, including stinging, burning, sneezing, and temporary nasal dryness.
Uncommon/Rare Systemic effects such as headache, dizziness, palpitations, and elevated blood pressure (hypertension), resulting from systemic absorption.
SOCs Involved Primarily Respiratory, Thoracic and Mediastinal Disorders (local effects) and Nervous, Cardiac, and Vascular Disorders (systemic effects).

Safety Constraints and Duration-Related Risks

The medicine's safety profile includes specific constraints regarding its duration of use and application in certain patient populations. The risk of rebound congestion (rhinitis medicamentosa) is explicitly documented as a safety pattern associated with prolonged use, typically when the spray is used for more than three to five consecutive days. This duration-related risk is the primary safety limitation for the general population.

Regulatory documentation also includes contraindications for specific groups. The product is often contra-indicated in children under 12 years due to the heightened risk of severe systemic toxicity, which can involve marked central nervous system depression. Additionally, caution is advised or use is contra-indicated in patients with pre-existing conditions such as severe hypertension, coronary artery disease, hyperthyroidism, and angle-closure glaucoma.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for this combination nasal spray is defined by the high risk of severe systemic toxicity following accidental ingestion, particularly in young children. Regulatory warnings emphasize that infants and children 5 years of age and younger are specifically documented as being especially sensitive to potentially fatal adverse events.

Due to this risk, the official directive is to seek emergency medical care immediately following any suspected swallowing of the solution. Caregivers must also contact the national toll-free Poison Help Line (1-800-222-1222) right away, as stated in official documents.

Documented severe manifestations involve the Central Nervous System (CNS) and Cardiovascular System. CNS effects may include sedation, stupor, lethargy, confusion, seizures, and progression to coma. Cardiovascular findings may present as profound changes in heart rate (bradycardia or tachycardia) and blood pressure (hypotension or hypertension). Life-threatening outcomes such as respiratory failure have been reported.

Management is strictly symptomatic and supportive. No specific antidote is known for the volatile oil components. Hospital monitoring is required, including the continuous observation of vital signs and ECG, due to the documented potential for serious cardiac and respiratory complications.

Advertisements

Therapeutic Uses of Neo Spray CAF

What Neo Spray CAF Treats: Main Uses and Benefits

Neo Spray CAF is commonly used for symptomatic relief in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. It is primarily relevant for easing symptoms that create noticeable physiological strain.

The medication is used for managing conditions that present with acute or episodic manifestations, including congestion associated with the common cold, sinus pressure, and seasonal allergies (hay fever). It helps address symptom clusters that may appear suddenly and interfere with daily comfort. It is commonly used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress.

The medication is considered relevant for easing symptoms that interfere with daily comfort and contributes to improved day-to-day comfort during periods of heightened symptoms. It is relevant when short-term symptomatic assistance is needed to cope more steadily with symptom fluctuations.


Quick Fact: Therapeutic Focus is Managing Nasal Congestion and Sinus Pressure

Regulatory References

  1. NIH DailyMed
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Neo Spray CAF

Official regulatory documents define strict criteria for the use of Neo Spray CAF, primarily based on age, existing medical conditions, and concurrent medication use. Eligibility is classified as Allowed, Conditional, or Contraindicated.

Allowed Population

Use is authorized under standard labeled conditions for adults and children 12 years of age and older.


Populations for Whom Use is Contraindicated

Classification Population Rationale/Restriction
Absolute Contraindication Children under 12 years of age Prohibited due to the risk of sedation if swallowed.
Absolute Contraindication Individuals taking Monoamine Oxidase Inhibitors (MAOIs) Prohibited for current use or within two weeks of stopping the MAOI drug.

Conditional Use (Consultation Required)

Individuals in the following categories must consult a healthcare professional before use due to potential physiological constraints or risks:

  • Chronic Comorbidities: Patients with heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to an enlarged prostate gland.
  • Reproductive Status: Individuals who are pregnant or breast-feeding.

These official statements define the required parameters for who can and who must not use the medicine, as documented in governmental labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Neo Spray CAF is defined by the sympathomimetic properties of Naphazoline, resulting in pharmacodynamic constraints and specific administration requirements documented in regulatory sources.

Interaction Scope and Restrictions

Element Regulatory Statement
Medicinal Product Categories Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), Other Sympathomimetic Agents, and specific intranasal drugs (e.g., Zavegepant).
Mechanistic Basis Primarily pharmacodynamic reinforcement (potentiating the pressor effect) and reduction of co-administered drug exposure.
Timing-based Rules When using Zavegepant intranasal, the decongestant must be administered at least 1 hour after Zavegepant to avoid reducing the latter's systemic exposure.
Food and Alcohol No known interactions documented with food or drinks. Interaction status with alcohol is classified as unknown.

Official Interaction Statements

  • Co-administration with MAOIs is strictly contraindicated due to the risk of a severe hypertensive crisis. This restriction applies for 14 days after stopping MAOI therapy.
  • The use of TCAs or Maprotiline may potentiate the pressor effect of Naphazoline, increasing the risk of elevated blood pressure.
  • The spray may reduce the efficacy of Iobenguane I 131 by interfering with catecholamine uptake.
  • Use should be discontinued prior to anesthesia involving agents such as Halothane or Cyclopropane, which sensitize the myocardium to sympathomimetics.

The official profile strictly addresses these known pharmacological overlaps and administration constraints, mandating formal contraindications and explicit timing rules as documented in prescribing information.

Advertisements

Mechanism of Action

How Neo Spray CAF Works

Neo Spray CAF utilizes two distinct, complementary pharmacodynamic mechanisms—one focused on vascular tone and one on sensory nerve signaling—to produce its physiological effects.


alpha-Adrenergic Agonism and Vascular Tone Modulation

The active ingredient, Naphazoline, engages the autonomic nervous system's control over blood flow through targeted receptor activation. Naphazoline acts as an agonist by binding to alpha-adrenergic receptors on the blood vessel walls in the nasal mucosa. This molecular interaction initiates a mechanistic cascade resulting in the contraction of vascular smooth muscle, or vasoconstriction. This physiological change reduces the volume of blood held in the tissue, directly resulting in a physical reduction of mucosal tissue volume and airway diameter.


Sensory Nerve TRPM8 Channel Activation

This mechanism involves the aromatic components, Camphor and Eucalyptol, which are applied to modulate peripheral sensory signaling. These molecules interact with and activate TRPM8 ion channels found on nerve endings in the nose. Activation of these specialized channels transmits a thermal sensory signal to the brain. This effect results in a rapid alteration of airflow perception, existing parallel to the physical reduction mechanism, even though the sensory activation does not physically alter the nasal tissue volume.


Mechanistic Synergy and Time-Course

The drug's overall profile relies on the combined co-action of the vasoconstrictive mechanism and the sensory modulation pathway. The combination of an objective reduction in tissue volume and a rapid alteration of sensory input allows the drug to influence both the physical state of the nasal passage and the immediate perception of airflow.

Advertisements

Dosage and Administration Information

How to Use Neo Spray CAF: Official Administration Guidelines

The administration of Neo Spray CAF focuses on precise dosing, frequency, and duration limits for Naphazoline Hydrochloride combination nasal sprays.


Administration Protocol

The medicine is designated for topical application to the nasal mucosa (nasal use only) as a liquid solution via a metered-dose pump spray. Proper preparation is required before use: the container must be shaken well, and the pump must be primed before the initial administration or after a period of non-use to ensure accurate dosing.

Feature Guideline
Dosing Schedule Adults and children 12 years of age and older: 2 or 3 sprays delivered into each nostril per dose.
Dosing Frequency Administration must occur no more often than every 10 to 12 hours. The total limit is 2 doses in any 24-hour period.
Maximum Duration The product is restricted to short-term use, and must not be used continuously for more than 3 days.
Pediatric Use Children under 6 years of age are officially excluded from using this product.

Procedural Constraints and Timing

The usage protocol establishes clear constraints on patient administration. The timing of use is independent of meals and other oral intake. If a dose is missed, it should be taken as soon as it is remembered, provided the next scheduled dose is more than 10 to 12 hours away; otherwise, the missed dose must be skipped to strictly adhere to the maximum daily limit. Additionally, the medication container should not be shared between individuals, which is a key procedural condition to prevent the spread of infection.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Neo Spray CAF


Evidence for Symptomatic Relief in Common Cold and Acute Rhinitis

Research exploring how symptoms change over time related to nasal congestion and associated discomfort consists primarily of short-term Randomized Controlled Trials (RCTs) examining single decongestants (like Naphazoline's class), alongside observational studies of the combination product. Studies monitored outcomes related to physical discomfort and nasal airflow.

Research describes patterns observed where changes in nasal airflow were seen in the short-term following application of the decongestant component. Findings related to the aromatic components (Camphor and Eucalyptol) reported patient experiences, including measurements related to the sensation of clearer breathing. However, this reported subjective feeling sometimes did not align with objective physiological measurements of nasal airflow resistance.

Research on Congestion Related to Allergies (Hay Fever)

The decongestant component was studied for conditions associated with acute episodes, such as allergic rhinitis. Evidence is often derived from Systematic Reviews and RCTs where decongestants were evaluated in comparison to other studied interventions. Studies report how symptoms evolved in populations presenting with cycles of stability and flare-ups, but the evidence mainly applies to the single symptom of congestion.

Evidence Behind the Combination Formula and Aromatic Components

Research examined the combination in settings with varying symptom burdens. The studies monitored two axes: physiological strain and patient-reported outcomes. Research describes that the aromatic components data show patterns related to an immediate cooling or sensory effect. Follow-up durations were limited in research focusing specifically on the three ingredients. The specific evidence for the outcomes related to this particular three-part combination over a single decongestant remains uncertain.

What is Still Uncertain About Neo Spray CAF Research

A primary limitation is that comparative evidence is lacking for the specific combination against other standard nasal decongestants. Furthermore, research focuses heavily on addressing short-term changes, meaning that long-term effects are not fully established. Subgroup findings are uncertain, as data for specific populations like children (under 12 years of age) or individuals with concurrent health issues remain limited.

Key Studies & References

  1. Therapeutic Potential of 1,8-Cineole in Respiratory Diseases with a Focus on Asthma, Sinusitis, and Upper Respiratory Tract Infections: A Comprehensive Review
  2. Label: NAFASOLINA- naphazoline hydrochloride solution/ drops - DailyMed - NIH
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neo Spray CAF (FAQ)

Q: Is Neo Spray CAF considered a steroid or a non-steroidal medicine?

The medicine is officially classified as an Alpha-Adrenergic Agonist, which is a type of decongestant, along with topical aromatic counterirritants. This classification means Neo Spray CAF is a non-steroidal medicine. This information is based on the pharmacological class defined in regulatory documents.

Q: Does Neo Spray CAF have any described benefits outside of its main approved purpose?

The primary approved use is for the temporary relief of nasal congestion. Official documentation also describes a complementary sensory effect from the aromatic ingredients (Camphor and Eucalyptol). This sensory effect may result in a rapid perception of clearer breathing, which runs parallel to the physical decongestant action.

Q: Are there any reported long-term health consequences or side effects from regular use of Neo Spray CAF?

Regulatory documents highlight that the main risk associated with prolonged use beyond the recommended duration is the development of rebound congestion, also known as rhinitis medicamentosa. This condition involves nasal stuffiness returning or worsening after the drug wears off, creating a potential reliance on continued use.

Q: Can using Neo Spray CAF cause feelings of drowsiness or impair the ability to drive or operate machinery?

Systemic absorption of the decongestant component may potentially lead to Central Nervous System (CNS) effects. Adverse reactions reported include dizziness, anxiety, or confusion. Regulatory documents state that users should be aware of how they respond to the medicine before operating machinery or driving.

Q: Is there a risk of becoming physically or psychologically dependent on Neo Spray CAF with prolonged use?

Official safety information documents the risk of rhinitis medicamentosa (rebound congestion) with prolonged use. This condition is a form of physiological reliance where the nasal passages may become dependent on the medicine for normal function.

Q: Does Neo Spray CAF affect mental focus?

The medicine's active component has the potential for minor CNS effects if it is absorbed systemically. Official reports list symptoms such as dizziness or confusion as possible, which may in turn alter one's usual mental focus.

Q: Are there documented withdrawal symptoms that can occur when stopping the use of Neo Spray CAF?

The sudden stop after using the spray for longer than recommended can lead to a return or worsening of congestion. This recurrence is the documented consequence known as rebound congestion. This pattern is considered a primary safety limitation of the product.

Q: What happens if I administer Neo Spray CAF alongside another type of nasal spray?

The official label specifically lists known interactions with particular intranasal medications, such as Zavegepant, which requires a time delay between administrations. It also warns against use with other sympathomimetic (decongestant) agents. Non-medicated products, such as saline sprays, do not generally have contraindications listed in the official profile.

Q: How fast can a patient typically expect to feel the effects after using Neo Spray CAF?

The primary active ingredient is clinically recognized for its rapid onset in reducing nasal airflow resistance. The aromatic components are also associated with an immediate cooling or sensory effect, influencing the perception of clear breathing.

Q: What is the typical duration of effect for a single administration of Neo Spray CAF?

The official administration schedule is determined by the duration of the medicine's effect. Regulatory guidelines state that dosing must occur no more often than every 10 to 12 hours within a 24-hour period.

Q: Is Neo Spray CAF specifically studied for safety and effectiveness in the elderly population (seniors)?

Official documentation includes a Conditional Use classification for individuals with common chronic conditions (e.g., heart disease, high blood pressure) often found in this group, indicating that consultation with a healthcare professional is necessary before use. Research documentation also indicates that specific subgroup findings for the elderly population remain limited.

Q: What is the overall level of research evidence that supports the approved uses of Neo Spray CAF?

The evidence base primarily consists of short-term randomized controlled trials and observational studies. Regulatory summaries note that the research is limited, specifically indicating a lack of comparative evidence against other standard decongestants and that long-term effects are not fully established.

Q: What are the official warnings about accidentally swallowing Neo Spray CAF?

The primary warning regarding accidental oral ingestion is the risk of sedation and systemic toxicity, particularly in children under 12 years of age. If an excessive amount of the drug is swallowed, official safety information mandates that immediate medical help be sought.

Q: What are the official guidelines for reporting or managing a serious adverse reaction to Neo Spray CAF?

Official safety information outlines the regulatory protocol which requires that immediate medical help be sought in the event of a serious adverse reaction or suspected overdose. This includes contacting a healthcare professional or reaching out to a Poison Control Center.

Q: Does Neo Spray CAF contain any known allergens or substances that commonly cause allergic reactions?

Regulatory information contains a general warning for individuals who may be allergic to any ingredient in the product formulation. The complete list of active and inactive components is provided on the product label for review.

Q: Is it safe to use Neo Spray CAF at the same time as over-the-counter pain relief medication?

The active ingredients do not have widely documented severe or moderate interactions with common over-the-counter pain relievers. This includes medicines containing acetaminophen or ibuprofen.

Q: Does Neo Spray CAF interact with common vitamin or mineral supplements like Vitamin D or iron?

Official guidelines include the protocol of informing a healthcare provider about all medicines, including over-the-counter medicines, vitamins, and herbal products. While specific interactions with common vitamins or minerals are not documented, this disclosure is a standard regulatory guideline.

Q: Is there any known interaction or consequence regarding caffeine intake and Neo Spray CAF?

Naphazoline is classified as a sympathomimetic agent. Regulatory documentation suggests that using this class of medicine with other Central Nervous System (CNS) stimulants, such as caffeine, may potentially increase the risk of side effects. These side effects could include nervousness, anxiety, or a fast heart rate.

Q: Does Neo Spray CAF have any known contraindications for people with liver or kidney conditions?

The official safety documentation does not list liver disease or kidney disease as contraindications. The contraindications section is focused on conditions such as severe hypertension, cardiac disease, and thyroid disease.

Q: Why is it important to use Neo Spray CAF exactly as described by the manufacturer?

Adherence to the administration schedule and maximum duration (e.g., no more than three days) is required to avoid the risk of documented adverse events. Overuse or prolonged administration is directly associated with the risk of developing rebound congestion or worsening of nasal symptoms.

Q: Does Neo Spray CAF affect the results of any standard medical laboratory tests?

Official interaction statements indicate the spray may reduce the efficacy of the diagnostic agent Iobenguane I 131. This is due to interference with the uptake of catecholamines, which is a documented form of medical test interaction.

Advertisements

How should Neo Spray CAF be stored and disposed of?

How to Store and Dispose of Neo Spray CAF?

The storage and disposal of this product must comply with official regulatory labeling, which treats the medicine as a temperature-sensitive aerosol spray.


Storage Requirements

Neo Spray CAF must be stored at or below 25 C (77 F), protected from sunlight and moisture. Due to its pressurized container, it must not be exposed to temperatures exceeding 50 C (122 F) and must be kept away from ignition sources. As a mandatory requirement, the product must be stored out of the sight and reach of children.


Disposal

Disposal of unused or expired product should follow local regulations, with an authorized drug take-back program being the preferred method. The pressurized container must not be pierced or burned, even when empty.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neo Spray CAF found in:

A-Z Index: